Patients with cervical carcinoma under radiotherapy have been fol lowed during and after radiotherapy for the incidence of chromosome aberrations in peripheral lymphocytes. In patients treated with adreno chrome monoguanylhydrazone methansulfonate (100 mg) before every irradiation the incidence was significantly lower than in those without the treatment.
Chemical protection has a history of more than 20 years. Many chemicals such as cysteine, cysteamine, AET, and serotonin have been reported to protect animals against lethal doses of ionizing radiations but none of them have been demonstra ted to protect human being. High toxicity of these chemicals has prevented their clinical application.
Recently Sugahara and his colleagues reported that adrenoch rome monoguanylhydrazone methansulfonate (AMM) is radioprotective at very low doses in mice and suggested a promising future for its clinical application1'2>. Ya mashita et al. has tried to demonstrate its protective effect in man by using ra diotherapy patients as materials'). Reduction in peripheral blood cell counts espe cially leucocyte count was much less in AMM-treated patients than in untreated controls. But because of a large physiological variation of these values it was very difficult to obtain statistically significant results. Many investigators did not agree with them to use leucocyte count as an indicator of radiation protection. 
